Rivastigmine (Exelon TM) in the treatment of senile dementia of the Alzheimer type (SDAT)

Stein K
Record ID 31999008356
Authors' objectives: To summarise the evidence for the cost effectiveness of rivastigmine, an acetylcholinesterase inhibitor taken twice daily, to be made available to people with mild to moderate SDAT (MMSE 10-26).
Authors' recommendations: The evidence, from a relatively large series of phase III trials, appears to be of moderate methodological quality, although important details are lacking and insufficient experience has been gained in trials to determine the appropriate duration of treatment. Overall, benefits are modest, subject to considerable uncertainty and are achieved at relatively high cost to the NHS, suggesting that rivastigmine is comparatively poor value for money. However, in a small proportion of people benefits are likely to be clinically significant. Treatment should therefore be targeted at those who show and sustain a response, which demands careful pre-treatment assessment and monitoring of response. Careful monitoring of adverse events is also required.
Authors' methods: Review
Project Status: Completed
URL for project: http://www.wihrd.soton.ac.uk
Year Published: 1998
URL for published report: n/a
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England
MeSH Terms
  • Rivastigmine
  • Cholinesterase Inhibitors
  • Costs and Cost Analysis
  • Dementia
  • Alzheimer Disease
Organisation Name: Wessex Institute for Health Research and Development
Contact Address: Pauline King. Wessex Institute for Health Research and Development, Boldrewood Medical School, Bassett Crescent East, Highfield, Southampton. SO16 7PX Tel. +44 1703 595661 Fax +44 1703 595662
Copyright: Wessex Institute for Health Research and Development (WIHRD)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.